HOME >> MEDICINE >> NEWS
NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks

nue for up to seven years.

The research structure resulting from this competition will enable NIAID's Division of AIDS to more effectively respond to global research needs, including those of people of color, those who live in poverty, and women, all of whom are increasingly affected by the HIV/AIDS pandemic and continue to be under-represented in clinical research.

"We are pleased to be making this announcement on World AIDS Day," says Dr. Fauci, "as this year's World AIDS Day theme focuses on 'Women, Girls, HIV and AIDS'."

Each network leadership group selected as part of this competition will work with NIAID and other NIH Institutes on a focused research effort. To most effectively coordinate across disciplines, each network can address significant scientific questions in one or more of six priority research areas

  • Developing HIV vaccines
  • Translating research insights into therapeutic products to treat HIV disease
  • Optimizing clinical management of HIV/AIDS, including co-infections and other HIV-related conditions
  • Developing microbicides to prevent HIV acquisition and transmission
  • Preventing mother-to-child transmission of HIV
  • Developing other methods of HIV prevention

    The decision to revamp the clinical research structure emerged following extensive consultations with researchers, clinicians, community, nurses, advocates and people living with and at risk for HIV/AIDS. The new approach is designed to increase the efficiency, accountability and integration of NIAID's HIV/AIDS clinical research networks and enhance their capacity to effectively conduct vital clinical research, especially in resource-limited settings. Specifically, the new clinical research structure will

  • Maximize scientific opportunities by integrating and coordinating HIV/AIDS prevention, vaccine and therapeutic research and maintaining a flexible and responsive approach to emerg
    '"/>


  • Contact: NIAID Press Office
    niaidnews@niaid.nih.gov
    301-402-1663
    NIH/National Institute of Allergy and Infectious Diseases
    1-Dec-2004


    Page: 1 2 3

    Related medicine news :

    1. NIAID initiates trial of experimental avian flu vaccine
    2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
    3. NIAID begins enrolling volunteers for novel HIV vaccine study
    4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
    5. NIAID launches influenza genome sequencing project
    6. NIAID launches program to improve medical tools against emerging infectious diseases
    7. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
    8. NIAID rotavirus vaccine licensed for commercialization
    9. Second NIAID SARS vaccine candidate helps mice fend off SARS
    10. NIAID vaccine protects against SARS virus infection in mice
    11. NIAID Ebola vaccine enters human trial

    Post Your Comments:
    (Date:3/6/2015)... Follow us on LinkedIn – ... drug refers to testing of absorption, distribution, metabolism, and ... toxicity studies are clubbed together with ADME, it is ... on lowering costs and time during drug development are ... drug development model uses toxicity and efficacy testing in ...
    (Date:3/6/2015)... USA (PRWEB) March 06, 2015 Parents ... the fatal reality of substance use disorders. School programs ... to be marginally successful. NOPE, or Narcotics Overdose Prevention ... nationwide, according to Healthline News on Feb. ... illicit and prescription opiate drugs, drug prevention proponents are ...
    (Date:3/6/2015)... 06, 2015 Johnson & Johnson and ... on March 5, 2015 in Superior Court in the ... documents, a jury of 12 awarded Mrs. Perry $700,000 ... implanted with an Ethicon TVT Abbrevo plastic sling for ... three women also awarded $5 million in punitive damages. ...
    (Date:3/6/2015)... DC (PRWEB) March 06, 2015 Magellan ... nation’s only comprehensive source for key trends and statistics ... spend, medical injectables. Executives from Magellan Rx Management will ... Trend Report: Discover Your Hidden Specialty Drug Spend,” a ... Information Services, Inc. , Specialty drug spend makes up ...
    (Date:3/6/2015)... 06, 2015 The Gluten-Free Certification ... Association, is pleased to announce that Dufflet Pastries, ... has expanded their product line of gluten-free treats ... scrumptious and as satisfying as any of their ... and never contains hydrogenated fats or oils, artificial ...
    Breaking Medicine News(10 mins):Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4
    (Date:3/6/2015)... WILMINGTON, Del. , March 6, 2015 /PRNewswire/ ... Patent and Trademark Office,s publication of U.S. Patent ... Eating Disorder."  The ,249 Patent Application features claimed methods ... may be used to treat Binge Eating Disorder ... "information material," or "flyer or an advertisement," as ...
    (Date:3/5/2015)... , March 5, 2015 BioLineRx (NASDAQ: ... biopharmaceutical company dedicated to identifying, in-licensing and developing ... commenced an underwritten public offering of American Depositary ... Ordinary Shares. All of the ADSs in the ... JMP Securities is acting as sole ...
    (Date:3/5/2015)... 5, 2015  IRIDEX Corporation (Nasdaq: IRIX ) ... ended January 3, 2015.  , Revenues were $11.8 ... the Company and up 11% from $10.6 million in the ... a record, up 12% from $38.3 million in 2013. ... up from 48.6% in the fourth quarter of the prior ...
    Breaking Medicine Technology:Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8
    Cached News: